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Background: Parathyroidectomy (PTX) is often performed in dialysis patients when medical treatment fails to
control secondary hyperparathyroidism (SHPT). PTX is viewed by many as a cost-containing measure for patients
who have been treated with vitamin D analogs and calcimimetics. Yet, information about health resource utilization
and costs before and after PTX is limited.
Methods: This retrospective cohort study used professional service and pharmacy claims to identify subjects on
dialysis undergoing PTX from 1/1/2008-12/31/2010. Only subjects with at least six months of information before
and after PTX were considered. Subjects with primary hyperparathyroidism or kidney transplant were excluded.
Prescription use, physician encounters, and surgical complications were compared during the six months
immediately before and after PTX.
Results: The mean (SD) age of the 181 study subjects was 51 (15) years; 59% female; and 80% insured by Medicare.
Overall, the percentage of patients receiving medications to manage altered mineral metabolism increased from
67% before to 79% after PTX. Specifically, oral vitamin D use increased, while the utilization of cinacalcet decreased
resulting in mean (SD) monthly medication charges decreasing from $486 (507) to $226 (288) (p < 0.01). The mean
(SD) number of physician encounters rose from 15 (14) before to 21 (22) per 6 months after PTX (p < 0.01) resulting
in the corresponding increase in mean (SD) monthly charges from $1531 (2150) to $1965 (3317) (p = 0.08).
Hypocalcemia was the predominant diagnosis recorded for post-surgical physician encounters occurring in 31% of
all subjects; 84% of hypocalcemic episodes were managed in acute care facilities.
Conclusions: The cost of medications to manage SHPT decreased after PTX largely due to reduction in cinacalcet
use, whereas vitamin D use increased likely to manage hypocalcemia. The frequency and cost of physician
encounters, especially in acute care settings, were higher in the 6 months after PTX attributable largely to episodes
of severe hypocalcemia. Overall, the reduction in prescription costs during the 6 months after PTX is outweighed
by the higher costs associated with physician care.
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Healthcare utilizationBackground
Secondary hyperparathyroidism (SHPT) associated with
alterations in bone and mineral metabolism is common in
patients with chronic kidney disease (CKD) [1-3]. SHPT
progresses over time manifesting as increasing parathyroid
gland hyperplasia and increasing synthesis of parathyroid
hormone (PTH). In patients with CKD on dialysis, SHPT
is characterized both by elevations in PTH as well as* Correspondence: vasilyb@amgen.com
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reproduction in any medium, provided the orabnormalities in calcium and phosphorus levels. Previous
studies [4,5] have reported that these biochemical abnor-
malities are associated with adverse health outcomes, in-
cluding elevated rates of bone fracture, cardiovascular
disease, and death [6-8]. It is recommended that patients
on dialysis should be monitored for serum calcium and
phosphorus every 1–3 months and for PTH every 3–
6 months [1], while the specific target levels of these bio-
markers are still being debated [9-15].
Pharmacological intervention for SHPT includes vita-
min D analogs, phosphate binders, and calcimimeticsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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glands, ie, parathyroidectomy (PTX) is considered when
patients fail to respond adequately to medical therapy
and is recommended in patients with severe HPT de-
fined by PTH > 800 pg/mL [17]. Parathyroidectomy is a
viable option for such patients according to the current
practice guidelines from the Kidney Disease: Improving
Global Outcomes (KDIGO) [18]; it generally improves the
short-term and long-term profile of biochemical markers
[18-21]. However, the major disadvantage of sub-total
PTX are the risks involved in operating in the anterior
neck if the patient should need a second surgery; while
the disadvantage of total PTX with autotransplant lies in
the possibility of prolonged hypocalcemia during the
waiting period for the auto transplanted parathyroid tissue
to become functional [21]. In a recent, comprehensive re-
view of therapeutic strategies, Stack, BC (2012) noted the
decline in parathyroidectomy rates in the US in the 1990s
and reported an observed favorable response five years
post surgery. Yet, the mortality rate is doubled compared
to non-operative SHPT patients and the risk of hypopara-
thyroidism is also increased, particularly for total PTX
with auto-transplantation [19]. Long term consequences
of PTX have not been studied sufficiently, mainly due to
the ethical issues around potential randomization. How-
ever, Kestenbaum et al. (2004) in an observational study of
Medicare claims found that patients had higher mortality
within 90 days post PTX, but better overall survival
12 months after the surgery compared to those receiving
medical therapy to control SHPT [22]. Also, improved
survival post-PTX has been reported by Iwamoto et al.
[23]. Chen et al. (1998) reported low mortality, short
length of hospital stay, and high patient satisfaction among
elderly patients undergoing PTX [24].
Based on the literature, PTX appears effective in lower-
ing PTH levels albeit not without risks. However, the
current literature remains scarce on the impact of parathy-
roid surgery on healthcare utilization and costs. The ob-
jective of our study was to better understand healthcare
utilization and charges before and after PTX among CKD
patients on dialysis.
Methods
This retrospective cohort study was based on the data
from private practice provider medical claims (Centers
for Medicare and Medicaid Services [CMS]; N = 1500 re-
cords), and National Council for Prescription Drug Pro-
grams prescription claims (NCPDP v5.2) in the IMS
database. The database contains approximately one bil-
lion submitted professional services claims per year, and
pharmacy claims for dispensed prescriptions from 50%-
60% of retail pharmacies across various geographic
regions in the United States. All patient-related informa-
tion is encrypted, de-identified, and compliant with theregulations of the Health Insurance Portability, Afford-
ability and Accountability 1996 (HIPAA 1996).
To be included in the study, patients were required
to have at least two professional service claims with
ICD-9-CM diagnoses for CKD stage 5 or end stage renal
disease (ESRD) at least 30 days apart, and one service
claim with the Current Procedural Terminology (CPT)
code of 60500, 60502 or 60505 for PTX procedure(s)
during January 2008 and December 2010. The index
date was the first procedure date of PTX. Further, pa-
tients were excluded from the study if they were youn-
ger than 18 years of age as of index date, had primary
hyperparathyroidism, or kidney transplant, or fewer
than six months of observation before and after PTX.
We analyzed, during the six months before and after
PTX, the pharmacy claims for drug prescriptions, phys-
ician encounters and corresponding charges, and surgical
complications recorded in the professional service claims
including hematoma or bleeding, vocal cord paralysis or
recurrent laryngeal nerve injury, hypocalcemia, wound in-
fection and seroma formation. Descriptive statistics, i.e.
means, standard deviation (SD) and median, were reported
for continuous variables; the number and percentage of
patients were reported for categorical variables. The paired
t-tests and McNemar tests were performed to assess the
differences before and after PTX. All the statistical analyses
were executed with Stata 12.1 (StataCorp LP. College
Station, TX).
Results
The present study identified 181 patients on dialysis
undergoing PTX between 2008 and 2010. Their mean
(SD) age was 51.1 (14.7) years. Female patients accounted
for 59.1% of the study cohort. Almost half of the study co-
hort inhabited the South census region and 80.1% were in-
sured by Medicare (Table 1).
Overall the study patients incurred the mean (SD)
charges of $4529 (2902) for physician care on the index
date – the date receiving PTX. (Table 2) The charges for
physician care on index date were mostly billed by surgeon
(80.7%) and from inpatient acute care facilities (80.7%).
Based on prescription filling activities in the pharmacy
claims, more patients received pharmacotherapy to man-
age SHPT-related biochemical abnormalities after PTX
than before (66.9% pre vs 75.8% post; p < 0.01) (Table 3).
The higher medication use post-surgery was mainly attrib-
uted to the increased use of oral vitamin D (calcitriol).
The percentage of patients filling scripts for vitamin D in-
creased from 11.6% pre- to 59.1% post-surgery (p < 0.01).
In contrast, the use of calcimimetics deceased from 34.8%
pre- to 11.6% post-surgery (p < 0.01). The use of phos-
phate binders remained stable before and after PTX.
While the study patients filled more prescriptions on aver-
age post-surgery compared to pre-surgery, their monthly
Table 1 Patient demography
N %
Number of patients 181 100%
Age
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from $486 (SD = 507) pre- to $226 (SD = 288) post-
surgery (p < 0.01).
Patients had more all-cause physician encounters after
PTX than before PTX (Table 4). The mean number (SD)
of all-cause physician encounters during a six-month
period increased from 15.1 (14.1) pre-surgery to 20.7
(22.0) post-surgery (p < 0.01). A higher percentage of pa-









Charges of physician care on index date, by service place
Emergent departments/urgent care centers 0
Inpatient acute care facilities 146
Office/outpatient clinics 3
Outpatient hospitals 62
Other/unknown service places 15
Abbreviation: NA not available.physician care team post-surgery than pre-surgery
(79.0% post vs 43.1% pre; p < 0.01); the mean (SD) of
six-month physician encounters in the acute inpatient
setting increased from 4.5 (9.3) pre-surgery to 10.5
(16.1) post-surgery (p < 0.01). However, physician en-
counters in the acute inpatient setting accounted for a
significant increase, whereas fewer patients had encoun-
ters in physician offices or outpatient clinics after the
surgery (70.2% post vs. 89.0% pre; p < 0.01). The average
physician encounters in the offices or outpatient clinics is
fewer during the six-month period of post-surgery than
prior to the surgery (3.5, SD = 4.6 post vs 4.3, SD = 5.1;
pre: p = 0.03). Healthcare charges billed by physicians also
had a marked increase after PTX (Table 5). The mean(SD)
monthly charges for all-cause encounters (excluding the
actual surgery costs) rose from $1531 (2150) pre-surgery
to $1965 (3317) post surgery (p = 0.08). The mean (SD)
charges in the acute inpatient setting increased signifi-
cantly from $681 (1474) pre-surgery to $1209 (1706) post-
surgery on average (p < 0.01). Furthermore, approximately
one-third of patients had evidence of possible surgery-
related complications identified in the professional service
claims. Hypocalcaemia was the most frequently diagnosed
condition related to surgery and accounted for 90% of pa-
tients with possible surgery-related complications (Table 6).
Discussions
This study presented the estimates of short-term
healthcare utilization and expenses before and after PTX
among patients on dialysis in the U.S. The results from
our study suggest that after PTX, the overall cost of medi-
cations to manage SHPT decreases largely because of the
reduction in the use of cinacalcet. However, vitamin D use
increases post-surgery, although the net effect on cost is
downward because of a shift to greater use of calcitriol asr (%) of patients Charges of physician care on index date
% Mean SD Median
100.0% 4,529 2,902 3,707
80.7% 3,742 2,060 3,212
31.5% 230 201 158
5.5% 711 1,595 211
51.4% 2,723 2,464 1,901
0.0% NA NA NA
80.7% 3,702 2,871 3,137
1.7% 870 849 675
34.3% 3,758 3,006 2,957
8.3% 2,914 2,349 2,110
Table 3 Prescription use and charges before and after Parathyroidectomy
Before (N = 181) After (N = 181) P value
Patients with medication use for: (N,%)
Any prescriptions for SHPT management 121 66.9% 142 78.5% <0.01
Calcimimetics 63 34.8% 21 11.6% <0.01
Bisphosphonates 0 0.0% 0 0.0% NA
Phosphate binders 98 54.1% 95 52.5% 0.7
Teriparatide 0 0.0% 0 0.0% NA
Raloxifen 1 0.6% 0 0.0% 1
Vitamin D 21 11.6% 107 59.1% <0.01
Number of filled scripts: (Mean, SD)
All prescriptions 22.8 20.4 27.9 23.3 <0.01
Prescriptions for SHPT management 2.6 3.3 3.2 3.2 0.05
Average monthly charges of scripts filled for: ($; Mean, SD)
All prescriptions 445 459 331 358 <0.01
Prescriptions for SHPT management 486 507 226 288 <0.01
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sumably for the management of hypocalcaemia. The fre-
quency and cost of physician encounters, especially in the
acute care setting, were higher in the 6-month period post
surgery. Hypocalcaemia was the dominant post-surgical
complication, and it was associated with additional phys-
ician care, often provided in the acute care setting. Overall,
the cost reduction in prescriptions during the 6-month
post surgical period was outweighed by the cost increase
associated with physician care.Table 4 Physician care before and after Parathyroidectomy
All-cause encounters in any place
N (%) of patients w/ ≥1 encounter
Mean (SD) of encounters
All-cause encounters in emergency departments/urgent care centers
N (%) of patients w/ ≥1 encounter
Mean (SD) of encounters
All-cause encounters in inpatient acute care facilities
N (%) of patients w/ ≥1 encounter
Mean (SD) of encounters
All-cause encounters in offices/outpatient clinics
N (%) of patients w/ ≥1 encounter
Mean (SD) of encounters
All-cause encounters in outpatient hospitals
N (%) of patients w/ ≥1 encounter
Mean (SD) of encounters
All-cause encounters in other/unknown service places
N (%) of patients w/ ≥1 encounter
Mean (SD) of encountersFrom the clinical standpoint, parathyroidectomy is often
reserved for the patients who have failed to respond to
medical therapy for SHPT. While clinical practice world-
wide is variable with respect to indications for and fre-
quency of utilization of PTX, one recent study reports
that the PTX rate in the US has fluctuated between 1992
and 2007 from the lowest recorded in 1998 (7.0 per 1000
patient years) to the highest during 2002 (12.8 per 1000
patient years) [25], which could reflect changing treatment
patterns and guidelines.Before (N = 181) After (N = 181) P value
181 100.0% 176 97.2% 0.06
15.4 14.1 20.7 22 <0.01
37 20.4% 56 30.9% 0.01
0.5 1.4 0.8 1.8 0.05
78 43.1% 143 79.0% <0.01
4.5 9.3 10.5 16.1 <0.01
161 89.0% 127 70.2% <0.01
4.3 5.1 3.5 4.6 0.03
88 48.6% 84 46.4% 0.63
1.5 2.9 1.5 3.1 0.92
105 58.0% 107 59.1% 0.69
4.7 6.5 4.5 6.7 0.7




(N = 181) P value
Average monthly charges of
encounters for any cause ($):
Any service places




Mean (SD) 81 216 155 370 0.01
Median 0 0
Inpatient acute care facilities
Mean (SD) 681 1,474 1,209 1,706 <0.01
Median 0 618
Physician offices/outpatient clinics
Mean (SD) 920 2,492 1,261 4,680 0.32
Median 250 152
Outpatient hospitals
Mean (SD) 587 1,539 603 1,209 0.89
Median 0 0
Other/unknown service places
Mean (SD) 440 827 391 531 0.41
Median 273 289
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economic standpoint arguably because of the ability to
save downstream costs of pharmacotherapies [26-28].
Our study highlights important short term clinical and
economic consequences of PTX which have not been
described previously. Although PTX is effective in lower-
ing serum PTH [29-34], it also commonly results in per-
sistent, inappropriately low PTH levels with the inherent
risk of hypocalcemia and adynamic bone disease [35-39].Table 6 Possible complications after surgery
N %
Number of patients 181 100%
Patients with any possible surgical complications 61 33.7%
Hematoma/bleeding 5 2.8%
Vocal cord paralysis/recurrent laryngeal nerve injury 1 0.6%
Severe hypocalcaemia 56 30.9%
Wound infection 1 0.6%
Seroma formation 1 0.6%
Mean (SD) of 6-month physician encounters for
possible complications
5.5 6.4
Mean (SD) of 6-month total charges of
physician encounters for possible complications ($)
1,009 959
Mean (SD) of monthly charges of physician
encounters for possible complications ($)
726 654Additionally, about 10-30% of CKD patients undergoing
either subtotal or total PTX still experienced persistent
or recurrent SHPT after the surgery [22-24,26,27,29].Limitations of study
This study has several limitations. Parathyroidectomy is not
a very common surgery within the general or CKD popula-
tion. The study design required at least six months of infor-
mation before and after PTX; the post PTX cost may have
been underestimated. The short study duration was se-
lected because there is no comparator group outside of
PTX and the design assumes the intervention of interest. In
addition, the study utilized the CPT codes of 60500, 60502
and 60505 to identify patients undergoing PTX. These CPT
codes cannot differentiate surgical procedures between total
PTX with autotransplantation, and subtotal PTX.
Race, or ethnicity, is generally not available in the pro-
fessional, medical service claims or pharmacy claims.
Thus, it is difficult to evaluate the differences of received
treatment and care utilization among different racial or
ethnic groups in this study.
This study did not find any claims activities related to
the use of IV vitamin D in private practitioner claims or
calcium supplement in the pharmacy claims. This is be-
cause such patients often receive injectable medications at
the dialysis centers making it likely to be recorded in the
medical charts in the centers or institutional claims (CMS-
1450 form) rather than in professional medical service claims
(CMS-1500 form) which was used in this study. Calcium
supplements are often available over-the-counter and not in-
cluded in the prescription formularies.
This study also attempted to bridge the information in
the medical and pharmacy claims with laboratory results
from a national laboratory provider in order to better
understand the changes of clinical endpoints such as
serum calcium, phosphorus, PTH and vitamin D before
and after PTX. However, there were only few patients
who had information available in both claims and la-
boratory data. It is conceivable that most dialysis pa-
tients’ routine blood work is captured within the dialysis
centers rather than in facilities outside dialysis centers.
Furthermore, the laboratory results are under-reported
in the professional service claims (CMS-1500 form) due
to the fact most of the laboratory results are not re-
quired for reimbursement of professional services.
The professional service and pharmacy claims largely
reflect the charges and payments for delivered health
services. Neither are designed for research needs to pro-
vide patient medical history to assess the disease severity
and progression, nor to evaluate cost as these claims
tend to be non-adjudicated claims. Finally, the con-
tinuum of care may not be fully observed in the claims-
based study since treatment may be provided at a
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practice site.
Conclusion
Our study showed that cost of medications to manage
SHPT decreased after PTX largely due to reduction in
cinacalcet use, whereas vitamin D (calcitriol) use in-
creased likely to manage hypocalcemia. The frequency
and cost of physician encounters, especially in acute care
settings, were higher in the 6 months after PTX attribut-
able largely to episodes of severe hypocalcemia. Overall,
the reduction in prescription costs during the 6 months
after PTX is outweighed by higher costs associated with
physician care. The impact of PTX on postoperative
healthcare utilization and charges may be a consider-
ation in the treatment decisions for dialysis patients for
whom all medical options have been exhausted.
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